• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SIOX

    Sio Gene Therapies Inc.

    Subscribe to $SIOX
    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

    IPO Year:

    Exchange: NASDAQ

    Website: siogtx.com

    Peers

    $NBRV
    $PASG
    $TSHA

    Recent Analyst Ratings for Sio Gene Therapies Inc.

    DatePrice TargetRatingAnalyst
    2/1/2022$10.00 → $7.00Buy
    HC Wainwright & Co.
    2/1/2022$6.00 → $1.00Outperform → Market Perform
    SVB Leerink
    10/21/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    8/12/2021$7.00 → $6.00Outperform
    SVB Leerink
    7/12/2021$12.50Buy
    Chardan Capital Markets
    See more ratings

    Sio Gene Therapies Inc. Financials

    Live finance-specific insights

    See more
    • Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis

      Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today pres

      10/21/21 5:30:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020

      - Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided financial results for its third fiscal quarter ended December 31, 2020. “In recent months, Sio Gene Therapies has made important progress in advancing its patient-fo

      2/9/21 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Sio Gene Therapies Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Sio Gene Therapies with a new price target

      HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $7.00 from $10.00 previously

      2/1/22 8:21:09 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Sio Gene Therapies from Outperform to Market Perform and set a new price target of $1.00 from $6.00 previously

      2/1/22 6:26:53 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sio Gene Therapies with a new price target

      HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      10/21/21 12:26:01 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Sio Gene Therapies with a new price target

      SVB Leerink reiterated coverage of Sio Gene Therapies with a rating of Outperform and set a new price target of $6.00 from $7.00 previously

      8/12/21 12:08:09 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets resumed coverage on Sio Gene Therapies with a new price target

      Chardan Capital Markets resumed coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $12.50

      7/12/21 7:29:29 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG initiated coverage on Sio Gene Therapies with a new price target

      BTIG initiated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $8.00

      6/15/21 7:04:03 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Sio Gene Therapies with a new price target

      H.C. Wainwright reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $8.00

      6/9/21 11:45:43 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Sio Gene Therapies with a new price target

      HC Wainwright & Co. initiated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $8.00

      4/30/21 6:11:58 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Sio Gene Therapies Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

      PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL"). In connection with the filing of th

      2/2/24 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

      –  Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively –  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period –  $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination

      2/14/23 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

      NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of the shareholders to dissolve and liquidate the Company," stated David Nassif, Chief Executive Officer. "The Board of Directors and management, together with its external advisors, devoted substanti

      12/14/22 4:49:43 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results

      - Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period - Strong cash position with $49.86 million of cash and cash equivalents as of September 30, 2022, expected to provide cash runway beyond December 2023 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal second quarter ended September 30, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination of the licenses to our three clini

      11/10/22 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results

      — Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal first quarter ended June 30, 2022. "Our financial results show the beneficial effects on operating expenses and cash resulting from the termination of the licenses to our three clinical-stage programs and the significant headcount reduction initiated in April. The winddown process of these programs will soon be concluded but the process will continue as we reduce our real estate footprint.

      8/11/22 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results

      NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth Quarter Financial Summary For the fourth fiscal quarter ended March 31, 2022, research and development expenses were $12.6 million, an increase of $4.4 million compared to the prior year quarter. The current period increase was primarily related to increased AXO-AAV-GM1 clinical trial material manufacturing expenses. General and administrative expenses for the fourth fiscal quarter ended March 31, 2022 were $0.5 million, a decrease of $3.5 million compared to the prior year quarter. $

      6/14/22 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Provides Corporate Update

      -Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB Securities to advise it on a range of strategic alternatives to maximize stockholder value-Company had cash and cash equivalents of approximately $64 million at March 31, 2022; license termination and related headcount reduction lowers operating expenses significantly NEW YORK and DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that it has provided the required notice to the University of Massachusetts to terminate its licensing agreement to develop and commercialize gene therapy product can

      4/27/22 4:25:26 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results

      Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9 million of cash and cash equivalents as of December 31, 2021, providing expected cash runway into calendar H2 2023 beyond the expected dates of major upcoming milestones for the AXO-AAV-GM1 and AXO-AAV-GM2 gene therapy programs NEW YORK and DURHAM, N.C., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided corporate upd

      2/11/22 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition

      – Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease, respectively; and to terminate AXO-Lenti-PD license agreement with Oxford Biomedica for Parkinson's disease – Portfolio prioritization allows company to focus resources and extends estimated cash runway into the second half of 2023 – David Nassif, current CFO and General Counsel of Sio, appointed interim CEO following resignation of current CEO and Board Director Dr. Pavan Cheruvu NEW YORK and DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-st

      1/31/22 4:01:00 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results

      –   Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF –   Granted Fast Track Designation for both AXO-AAV-GM1 and AXO-AAV-GM2 for the treatment of GM1 gangliosidosis and Tay-Sachs/Sandhoff disease –   Three AXO-Lenti-PD GMP campaigns successfully completed fill and finish, achieving target titers using suspension-based manufacturing process; on-track to complete certification of clinical trial material in Q4 2021 –   $101.7 million of cash and cash equivalents as of September 30, 2021, providing cash runway into calendar Q4 2022 NEW YORK and DURHAM, N.

      11/12/21 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Sio Gene Therapies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)

      SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/13/23 8:53:10 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sio Gene Therapies Inc.

      SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/10/23 4:00:19 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)

      SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/14/22 1:57:46 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/26/21 4:24:47 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/16/21 4:27:47 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/16/21 2:40:51 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/16/21 9:00:31 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Sio Gene Therapies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Sio Gene Therapies Inc. SEC Filings

    See more
    • SEC Form 4 filed by Meswani Parag V

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/10/22 5:07:32 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Nassif David W.

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/10/22 5:05:27 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Meswani Parag V claimed ownership of 33,733 shares

      3 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/7/22 7:17:01 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Nassif David W. was granted 17,534 shares and covered exercise/tax liability with 6,294 shares, increasing direct ownership by 33% to 45,244 units (withholding obligation)

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      12/9/21 6:31:32 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cheruvu Pavan was granted 37,567 shares and covered exercise/tax liability with 14,884 shares, increasing direct ownership by 13% to 203,109 units to cover taxes

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      12/9/21 6:31:14 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vuori Kristiina MD

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      4/19/21 4:59:14 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Torti Frank

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      4/19/21 4:57:48 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sundaram Senthil Vel

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      4/19/21 4:56:48 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pande Atul

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      4/19/21 4:55:29 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Modig Berndt

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      4/19/21 4:54:40 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Sio Gene Therapies Inc.

      15-12G - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/25/23 4:04:47 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sio Gene Therapies Inc.

      EFFECT - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/25/23 12:15:08 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Sio Gene Therapies Inc.

      POS AM - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/17/23 4:15:20 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Sio Gene Therapies Inc.

      S-8 POS - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/17/23 4:12:08 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Sio Gene Therapies Inc.

      25-NSE - Sio Gene Therapies Inc. (0001636050) (Subject)

      4/12/23 8:52:19 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Sio Gene Therapies Inc.

      25 - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/6/23 4:07:30 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/6/23 4:06:36 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sio Gene Therapies Inc.

      DEFA14A - Sio Gene Therapies Inc. (0001636050) (Filer)

      3/16/23 9:36:06 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Sio Gene Therapies Inc. (0001636050) (Filer)

      3/15/23 4:25:12 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFM14A filed by Sio Gene Therapies Inc.

      DEFM14A - Sio Gene Therapies Inc. (0001636050) (Filer)

      2/21/23 4:05:32 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care